In today’s briefing:
- Last Week in Event SPACE: Mitsui Matsushima, L’Occitane, Prosus/Tencent, EOFlow
- Legend Biotech Corporation: Implementation of Commercial Launch of CARVYKTI & Other Major Drivers
- Royalty Pharma: Identifying and Investing in Future Fields of Biopharma Innovation! – Major Drivers
- Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers
- Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! – Major Drivers
Last Week in Event SPACE: Mitsui Matsushima, L’Occitane, Prosus/Tencent, EOFlow
- Murakami-San now owns far more in Mitsui Matsushima (1518 JP) than he can easily get out of other than by corporate action. Murakami-san is not a dumb guy. He knows this.
- The unique investigative shareholder register confirms what has been long rumoured about a certain shareholder activist in L’Occitane (973 HK). It is also informative for what isn’t present.
- Prosus (PRX NA)‘s discount to NAV and implied stub widened after Fabricio Bloisi’s CEO appointment the previous week. But the sell-down of Tencent (700 HK) to buy-back Prosus will continue.
Legend Biotech Corporation: Implementation of Commercial Launch of CARVYKTI & Other Major Drivers
- Legend Biotech Corporation is a biotech company specializing in CAR-T cell therapy for the treatment of multiple myeloma.
- In Quarter 1 2024, two major approvals by the US Food and Drug Administration (FDA) and European Commission for the company’s CARVYKTI therapy for second line relapsed or refractory multiple myeloma have solidified its position in the industry.
- This historical quarterly update positions Legend Biotech’s CARVYKTI on the path to transforming the treatment landscape for thousands of patients suffering from multiple myeloma.
Royalty Pharma: Identifying and Investing in Future Fields of Biopharma Innovation! – Major Drivers
- Within the first quarter of 2024, Royalty Pharma displayed impressive performance, managing 14% growth in royalty receipts, thereby underlining the benefits of its diversified portfolio encompassing over 35 commercial products.
- However, it is important to note a decline for milestones and other contractual payments, which were mainly affected by a high base of the year-ago quarter due to a single nonrecurring Biohaven-related payment.
- Portfolio Receipts, as a result, decreased to $717 million, aligning with the company’s expectations.
Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers
- In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business.
- This was mainly led by the oncology and vaccines segments, where sales of KEYTRUDA and GARDASIL respectively saw significant increases.
- Merck’s first quarter results reflect the robust demand for its innovative portfolio, which has led to the company updating their full year guidance.
Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! – Major Drivers
- Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.
- These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.
- Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
